Plain language summary Immunotherapy has demonstrated high efficacy in lung cancer and is commonly used in clinical practice. Despite the good tolerability, severe immune-related adverse events may occur, requiring hospitalization and possibly leading to death. We present a case of vanishing bile duct syndrome (a rare and potentially lethal condition characterized by progressive destruction of small bile ducts) which arose a few days after the first pembrolizumab infusion. Laboratory tests and radiological imaging were performed to orient diagnosis and monitor disease; a histological sample was required for vanishing bile duct syndrome diagnosis. High-dose steroid therapy and immunosuppressors were administered, with scarce efficacy. Prompt recognition and management of similar conditions is crucial to avoid fatal events. Further studies are needed to investigate new drugs for steroid-refractory conditions.

Gemelli, M., Carbone, M., Abbate, M., Mancin, M., Zucchini, N., Colonese, F., et al. (2022). Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature. IMMUNOTHERAPY, 14(4 (1 March 2022)), 175-181 [10.2217/imt-2021-0078].

Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature

Carbone M.;Abbate M. I.;Invernizzi P.;Bidoli P.;Cortinovis D.
2022

Abstract

Plain language summary Immunotherapy has demonstrated high efficacy in lung cancer and is commonly used in clinical practice. Despite the good tolerability, severe immune-related adverse events may occur, requiring hospitalization and possibly leading to death. We present a case of vanishing bile duct syndrome (a rare and potentially lethal condition characterized by progressive destruction of small bile ducts) which arose a few days after the first pembrolizumab infusion. Laboratory tests and radiological imaging were performed to orient diagnosis and monitor disease; a histological sample was required for vanishing bile duct syndrome diagnosis. High-dose steroid therapy and immunosuppressors were administered, with scarce efficacy. Prompt recognition and management of similar conditions is crucial to avoid fatal events. Further studies are needed to investigate new drugs for steroid-refractory conditions.
Articolo in rivista - Articolo scientifico
immune-related adverse events; immune-related hepatitis; immunotherapy; lung cancer; pembrolizumab; vanishing bile duct syndrome;
English
7-dic-2021
2022
14
4 (1 March 2022)
175
181
none
Gemelli, M., Carbone, M., Abbate, M., Mancin, M., Zucchini, N., Colonese, F., et al. (2022). Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature. IMMUNOTHERAPY, 14(4 (1 March 2022)), 175-181 [10.2217/imt-2021-0078].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/350917
Citazioni
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 5
Social impact